EP Patent

EP2661434A4 — NEW URGES FOR THE TREATMENT AND PREVENTION OF CANCER

Assigned to Beta Pharma Canada Inc · Expires 2014-07-09 · 12y expired

What this patent protects

Patent listed against Zelboraf.

Drugs covered by this patent

Patent Metadata

Patent number
EP2661434A4
Jurisdiction
EP
Classification
—
Expires
2014-07-09
Drug substance claim
No
Drug product claim
No
Assignee
Beta Pharma Canada Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.